Dufaston (degidrosteron) in treatment of dysfunctional womb bleeding associated with ferrum hyperplasia of endometrium

Е. A. Ulrikh; G. F. Kutusheva; А. F. Urmancheeva

doi:10.17816/JOWD88982

Journal of obstetrics and women's diseases ›› 2003, Vol. 52 ›› Issue (3) : 60 -63. DOI: 10.17816/JOWD88982

Original study articles

review-article

Dufaston (degidrosteron) in treatment of dysfunctional womb bleeding associated with ferrum hyperplasia of endometrium

Author information +

History +

PDF

Abstract

Endometrial hyperplasia, being a fairly common gynecological pathology among women of different age groups, requires timely diagnosis and adequate treatment. Duphaston at a dosage of 10-20 mg from 5 to 25 or from 16 to 25 days of the menstrual cycle showed itself as an effective drug (in 83.3%), with sufficient progestogenic antiproliferative activity, with minimal side effects and a neutral effect on the metabolism of lipids and carbohydrates , which made it possible to use it among patients with various somatic pathologies.

Keywords

endometrial hyperplasia / dysfunctional uterine bleeding / dydrogesterone (duphaston)

Cite this article

Download citation ▾

Е. A. Ulrikh, G. F. Kutusheva, А. F. Urmancheeva. Dufaston (degidrosteron) in treatment of dysfunctional womb bleeding associated with ferrum hyperplasia of endometrium. Journal of obstetrics and women's diseases, 2003, 52(3): 60-63 DOI:10.17816/JOWD88982

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Бохман Я.В. Руководство по онкогинекологии. — Л.: Медицина, 1989. - 464 с.

[2]	ACNM clinical bulletin по.б-January 2002. Abnormal and Dysfunctional Uterine Bleeding. Journal of Midwifery & Women's Health. - 2002 May/June; 47(3).

[3]	Amezcua C.A., Zheng W., Muderspach L.I., Felix J. C. Downregulation of bcl-2 is a potential marker of the efficacy of progestin therapy in the treatment of endometrial hyperplasia. Gynecol. Oncol. - 1999 Apr.; 73(l): 126-36.

[4]	Amezcua C.A., Lu J.J., Felix J.C., Stanczyk F.Z., Zheng W. Apoptosis may be an early event of progestin therapy for endometrial hyperplasia. Gynecol. Oncol. — 2000 Nov.; 79(2): 169-76.

[5]	Brun J.L., Belaisch J., Rivel J., Носке C. Endometrial hyperplasias resistant to progestins: alternatives to traditional treatments. Gynecol. Obstet. Fertil. 2002 Mar.; 30(3):244-51.

[6]	Hunter J.E., Tritz D.E., Howell M.O., De Priest P.D., Gallion H.H., Andrews S.J., Buckley SB., Kryscio R.J., van Nagell Jr. J.R. The Prognostic and Therapeutic Implications of Cytologic Atypia in Patients with Endometrial Hyperplasia. Gynecol Oncol. - 1994 Oct;55(l):66-71.

[7]	Novak's Gynecology ed. Baltimor, 1996; 12:149-175.

[8]	Shah A.A., Grainger D.A., Contemporary Concepts in Managing Menorrhagia. Medscape Womens Health. - 1996 Dec.; 1(12):8.

[9]	Shaw R.W., Shaw H.A., Price T.M., Talavera E, Barnes A.D., GauppF.B., Shulman L.P. Menorrhagia. Br. J. Obstet. Gynecol. 2002 Jul.; 101(11):15-8.

[10]	Silverberg S., Kurman R. Tumors of the uterine corpus and gestational trophoblastic disease. Armed forces institute of pathology, Washington, D.C. 1992. Atlas of tumor pathology, Third Series, Fascicle 3.